PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, ...

Kurdikar emphasized progress on Embecta’s branding transition, which involves packaging and branding changes to establish the company independently with patients, healthcare professionals, and channel partners. He said more than 95% of U.S. and Canadian revenue has now transitioned to the Embecta brand. The next phase is rolling out internationally, with transitions underway in select markets and most regions expected to be “substantially complete” by the end of calendar year 2026.With that work largely com ...

Financial Performance - Revenues decreased by $0.7 million, or 0.3%, to $261.2 million for the three months ended December 31, 2025, compared to $261.9 million for the same period in 2024[115] - Gross profit increased by $4.6 million to $161.7 million, with a gross profit margin of 61.9%, up from 60.0% in the prior year[117] - Operating income surged by $54.6 million to $83.3 million, compared to $28.7 million in the previous year[117] - Net income reached $44.1 million, a significant increase from $0.0 million in the prior year[117] - Cost of products sold decreased by $5.3 million, or 5.1%, to $99.5 million, representing 38.1% of revenues, down from 40.0%[118] - Selling and administrative expenses fell by $3.5 million, or 4.3%, to $77.6 million, primarily due to lower compensation expenses[119] - Research and development expenses dropped by $15.7 million, or 77.3%, to $4.6 million, reflecting the discontinuation of the insulin patch pump program[120] Debt and Liquidity - As of December 31, 2025, Embecta's total principal debt issued amounted to $1,379.3 million, with long-term debt at $1,352.9 million after accounting for current debt obligations and issuance costs[128][130] - Embecta's total debt as of December 31, 2025, was $1,362.4 million, with short-term debt constituting 0.7% of total debt and a weighted average cost of total debt at 6.1%[128] - The company made interest payments of $13.2 million on outstanding debt during the three months ended December 31, 2025, and paid approximately $37.5 million on the Term Loan, of which $35.1 million was discretionary[130] - Cash and equivalents, along with restricted cash, decreased to $204.4 million as of December 31, 2025, down from $228.6 million as of September 30, 2025, primarily due to financing activities[138] - The company maintains sufficient liquidity through cash, cash equivalents, and borrowing capacity to meet operational and growth needs[127] - The effective tax rate decreased to 25.1% from 100.0% in the prior year, due to changes in earnings mix and lower limitations on interest expense deductibility[126] Operational Risks and Challenges - Future cash flows and financial performance are subject to various risks, including competitive factors and the ability to replace services currently provided by BD[147] - Operating costs have increased due to new tariffs imposed by the U.S. and foreign governments, affecting raw materials and energy costs[149] - The company faces risks from the global trade environment, with potential shifts in customer preferences towards local products due to tariffs[149] - Changes in reimbursement practices and foreign currency exchange rates could adversely impact financial performance[149][150] - Interest rate risk is primarily related to the Term Loan, with a potential $6.8 million impact on interest expense from a 100 basis point change in rates[153] - The impact of geopolitical instability and pandemics on operations and supply chains remains a concern for the company[149] Strategic Initiatives - The company is focused on the expected benefits of its Separation from BD and the associated risks of dis-synergy costs[149] - There are risks related to the completion of strategic partnerships and acquisitions that could accelerate growth and access to new technologies[149] - The company is undergoing a Patch Pump Program Restructuring Plan and a 2025 Restructuring Plan, with expectations on costs and profitability[149] - The ability to obtain FDA clearance for new products is critical for the company's future business decisions and market success[149] - The company has entered into foreign currency forward exchange contracts to manage currency exposure, which helps offset gains and losses[151][152] Credit Ratings and Compliance - Embecta's credit ratings were reaffirmed by Moody's at B1 and by Standard & Poor's at B+ in early 2026[136] - The company is in compliance with all financial covenants related to its credit agreements as of December 31, 2025[128]

Financial Data and Key Metrics Changes - In Q1 fiscal year 2026, Embecta generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [15] - GAAP gross profit for Q1 2026 totaled $161.7 million with a margin of 61.9%, compared to $151.7 million and 60% in the prior year [19] - GAAP net income for Q1 2026 was $44.1 million, with earnings per diluted share of $0.74, compared to zero in the prior year period [22] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7% due to continued insourcing by Becton Dickinson [18] Market Data and Key Metrics Changes - U.S. revenue for Q1 totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and volumes [15] - International revenue for Q1 totaled approximately $130 million, representing an increase of 8.4% on a reported basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is in the seed growth phase, focusing on staying competitive in core markets, selectively expanding the portfolio, and building financial flexibility through disciplined capital allocation [7] - A significant initiative is the brand transition to establish Embecta as an independent company, with over 95% of U.S. and Canadian revenue transitioned to the Embecta brand [8] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, with ongoing market dynamics impacting performance [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is collaborating with over 30 pharmaceutical partners on GLP-1 therapies, with several partners already selecting Embecta as a supplier [10] - The company expects to generate between $180 million and $200 million in free cash flow for 2026, although closer to the low end of that range [26] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [31][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that oral therapies are expanding the market rather than pulling patients away from injectables [36][39]

Financial Data and Key Metrics Changes - In the first quarter of fiscal year 2026, the company generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [15] - GAAP gross profit and margin for the first quarter totaled $161.7 million and 61.9%, compared to $151.7 million and 60% in the prior year period [19] - GAAP net income and earnings per diluted share were $44.1 million and $0.74 during the first quarter, compared to 0 in the prior year period [22] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7% due to the continued insourcing of these products by Becton Dickinson [18] Market Data and Key Metrics Changes - U.S. revenue for the quarter totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis [15] - International revenue for the first quarter totaled approximately $130 million, representing an increase of 8.4% on a reported basis and an increase of 4.6% on an adjusted constant currency basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is focused on transitioning to a broader medical supplies company and drug delivery partner, building on its foundation as a leader in global insulin delivery [8] - The brand transition initiative aims to establish Embecta as an independent company, with over 95% of U.S. and Canadian revenue transitioned to the Embecta brand [9] - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners, and expects initial generic GLP-1 launches in markets such as Canada, Brazil, China, and India beginning in calendar year 2026 [11] Management's Comments on Operating Environment and Future Outlook - Management expects to be closer to the lower end of the financial guidance ranges due to incremental U.S. pricing headwinds, while the international business outlook has improved [18][25] - The company anticipates a recovery in China in the second half of the year, with ongoing market dynamics and geopolitical factors impacting performance [32] Other Important Information - The company generated approximately $17 million in free cash flow during the first quarter and repaid approximately $38 million of outstanding debt, reducing net leverage to approximately 2.8 times [24] - The company reaffirmed its financial guidance for fiscal year 2026, expecting revenue to be flat to down 2% compared to 2025 levels [25] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in U.S. revenue driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [30][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [42][43] Question: Can you elaborate on the GLP-1 opportunity and the impact of new oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that the market for orals is expanding rather than pulling patients away from injectables [36][39]

Financial Data and Key Metrics Changes - In the first quarter of fiscal year 2026, the company generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [14] - GAAP gross profit and margin for the first quarter totaled $161.7 million and 61.9%, compared to $151.7 million and 60% in the prior year period [19] - GAAP net income and earnings per diluted share were $44.1 million and $0.74 during the first quarter, compared to $0 in the prior year period [21] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7%, primarily due to the continued insourcing of these products by Becton Dickinson [17] Market Data and Key Metrics Changes - U.S. revenue for the quarter totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and lower volumes [15] - International revenue for the first quarter totaled approximately $130 million, representing an increase of 8.4% on a reported basis and an increase of 4.6% on an adjusted constant currency basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is focused on transitioning to a broader medical supplies company and drug delivery partner, with a strong emphasis on brand transition and portfolio expansion [6][7] - The company aims to strengthen its core business while selectively expanding its portfolio in areas that leverage existing strengths, particularly in the Medicare Part D channel [9][10] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, given ongoing market dynamics and geopolitical factors [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners, with initial generic GLP-1 launches anticipated in markets such as Canada, Brazil, China, and India beginning in calendar year 2026 [11][12] - The company generated approximately $17 million in free cash flow during the first quarter and repaid approximately $38 million of outstanding debt, reducing its net leverage level to approximately 2.8 times [23][24] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [30][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that the market for orals is expanding rather than pulling patients away from injectables [36][38]

Earnings Conference Call Fiscal Q1 2026 February 5, 2026 1 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results from operations, performance, financial condition, goals, strategies, plans and achievemen ...

FOR IMMEDIATE RELEASE Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Feb 5, 2026 (GLOBE NEWSWIRE) – Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2025. "During the first quarter our results were largely consistent with our expectations," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "As we look ah ...

Group 1 - Embecta Corp. reported its first quarter fiscal 2026 financial results, continuing its evolution from a company focused on insulin delivery to a broader medical supplies company [1] - The company has a 100-year legacy in insulin delivery and aims to improve lives through innovative solutions and partnerships [3] Group 2 - A conference call and live audio webcast for analysts and investors was scheduled for February 5, 2026, at 8:00 a.m. ET, with a replay available later in the day [2]

Core Viewpoint - Embecta Corp. is transitioning from a company focused solely on insulin delivery to a broader medical supplies company, leveraging its 100-year legacy in the industry [1][3]. Group 1: Financial Results and Operational Update - Embecta will host a conference call on February 5, 2026, at 8:00 a.m. ET to discuss its fiscal first quarter 2026 financial results and provide an operational update [1]. Group 2: Accessing the Conference Call - Participants can access the live webcast of the conference call through the company's website or via a teleconference link [2]. - A replay of the call will be available starting at 11:00 a.m. ET on February 5, 2026, and will be archived for one year [2]. Group 3: Company Overview - Embecta employs approximately 2,000 employees globally and aims to improve lives through innovative solutions and partnerships [3].